Clinical Guidelines

AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in <em>KMT2A</em>-Rearranged Acute Leukemia

In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable res...

Share

  • 1

    Revumenib demonstrated clinically meaningful activity in heavily pretreated patients with relapsed or refractory KMT2A-rearranged acute leukemia.

  • 2

    The drug showed high rates of response and measurable residual disease negativity.

  • 3

    KMT2A-rearranged leukemia has a poor prognosis, and there is currently no approved treatment targeting the menin-KMT2A interaction.

  • 4

    Safety profile of revumenib was encouraging, with manageable toxicities.

  • 5

    The study provided insights into a novel treatment approach for a challenging type of leukemia.

Original Source(s)

AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in <em>KMT2A</em>-Rearranged Acute Leukemia

  • by Caroline Helwick

  • February 16, 2024

Related Content

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

AML Complexity Uncovered: A Unified Whole Genome and Informatics Approach for High Resolution Disease Understanding

Standard-of-care (SOC) genomic testing in acute myeloid leukemia (AML) has historically resulted in fragmented, incomplete genomic profiles that mask clinically significant biology.

  • March 12, 2026

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...